Key facts
- This page summarizes Bruce Turner's Form 4 filing for Immunome Inc. (IMNM).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 13 Aug 2024, 17:48.
Bruce Turner - 09 Aug 2024 Form 4 Insider Report for Immunome Inc. (IMNM)
- Reporting relationship
- Chief Strategy Officer
- Issuer ticker
- IMNM
- Reported as of
- 09 Aug 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 13 Aug 2024, 17:48:33 UTC
- Prior SEC filing
- 04 Oct 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Sandra Stoneman, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Bruce Turner filed Form 4 for Immunome Inc. (IMNM) on 13 Aug 2024.
Change
- Previous filing in this sequence was filed on 04 Oct 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
IMNM
transaction
Derivative
Stock option (right to buy)
Award
- Transaction value
- $0
- Shares
- +110,000
- Change %
- Price
- $0.000000
- Shares after
- 110,000
- Date
- 09 Aug 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 110,000
- Exercise price
- $12.92
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
25% of the shares subject to the options vest on August 9, 2025, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter.